Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vivos TherapeuticsVVOS +6.64%30 Cash-to-Debt is 0.14 as of Jun. 2026, which is 92% below its 10-year median of 1.78. GuruFocus rates VVOS with a GF Score™ of 30/100 and a GF Value™ of $0.89 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 842 Medical Devices & Instruments companies, Vivos Therapeutics ranks worse than 87.89% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vivos Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.14.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Vivos Therapeuticscouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Vivos Therapeutics's Cash-to-Debt or its related term are showing as below:
VVOS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13 Med: 1.78 Max: 27.03
Current: 0.14
During the past 8 years, Vivos Therapeutics's highest Cash to Debt Ratio was 27.03. The lowest was 0.13. And the median was 1.78.
VVOS's Cash-to-Debt is ranked worse than 87.89% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.61
vs VVOS: 0.14
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Vivos Therapeutics Cash-to-Debt Related Terms
Vivos Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Vivos Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, Vivos Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivos Therapeutics Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vivos Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Vivos Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivos Therapeutics (VVOS) has a Cash-to-Debt of 0.14 as of Jun. 2026. This is 92% below median its historical median of 1.78. Over the past decade, Vivos Therapeutics' Cash-to-Debt has ranged from 0.13 to 27.03. According to the industry distribution chart, Vivos Therapeutics ranks #740 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 87.9%.
Is Vivos Therapeutics' Cash-to-Debt too high?
Vivos Therapeutics' current Cash-to-Debt of 0.14 is 92% below median its 10-year median of 1.78. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 27.03. The Medical Devices & Instruments industry median Cash-to-Debt is 1.61. Vivos Therapeutics' value of 0.14 is 91.3% below this industry median. Based on the distribution chart, Vivos Therapeutics ranks #740 out of 842 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Vivos Therapeutics has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vivos Therapeutics' Cash-to-Debt compare to XAIR and USAQ?
According to the Medical Devices & Instruments industry distribution chart, Vivos Therapeutics ranks #740 out of 842 companies for Cash-to-Debt. This places Vivos Therapeutics in the lower half of its industry. The industry median Cash-to-Debt is 1.61. Vivos Therapeutics' value of 0.14 is 91.3% below this benchmark. Historically, Vivos Therapeutics' own Cash-to-Debt has ranged from 0.13 to 27.03 over the past decade. While the company's 10-year median is 1.78 vs. the industry median of 1.61, Vivos Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.61, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vivos Therapeutics's current Cash-to-Debt of 0.14 is 91.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivos Therapeutics's current Cash-to-Debt is 0.14, which is 92% below median its own 10-year median of 1.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vivos Therapeutics (VVOS) is currently considered Possible Value Trap. The stock's GF Value™ is $0.89, compared to a current price of $0.19 — trading 79.1% below its estimated fair value. The current Cash-to-Debt is 0.14, which is 92% below median its 10-year median of 1.78 and 91.3% below the Medical Devices & Instruments industry median of 1.61. Vivos Therapeutics' overall GF Score™ is 30/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Vivos Therapeutics (VVOS), the current Cash-to-Debt is 0.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vivos Therapeutics (VVOS) Overvalued in 2026?
Based on GuruFocus' analysis, Vivos Therapeutics stock appears to be undervalued.
The current stock price of $0.19 is trading 79.1% below its estimated GF Value™ of $0.89.
GuruFocus considers Vivos Therapeutics to be Possible Value Trap.
Key valuation signals for VVOS:
Cash-to-Debt: 0.14 (92% below median its 10-year median of 1.78)
GF Value™: $0.89 vs. price of $0.19 (79.1% below fair value)
Industry Position: 91.3% below the Medical Devices & Instruments median (#740 of 842)
No single metric tells the full story. See the VVOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
30GF Score
Get the complete analysis for VVOS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VVOS has been successfully added to your 
